MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer.

J TangH PanW WangC QiC GuAnquan ShangJ Zhu

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)

Taken together, miR-143-3p and miR-495-3p co-target CDK1, thereby inhibiting the occurrence and development of cervical cancer.

Keyphrases

cell cycle
risk assessment
signaling pathway